Genmab A (GMAB) Restructuring Costs (2024 - 2026)

Genmab A (GMAB) reported Restructuring Costs of -$45.0 million for Q1 2026, down 1400.0% quarter-over-quarter from -$3.0 million in Q3 2024.

Genmab A (GMAB) Restructuring Costs (2024 - 2026) Analysis & Trends

Genmab A has reported Restructuring Costs for 2 years, with the latest figure at -$45.0 million in Q1 2026.

For the quarter ending Q1 2026, Restructuring Costs changed N/A year-over-year to -$45.0 million; the trailing twelve-month figure through Mar 2026 stood at -$73.0 million (changed N/A YoY), and the FY2025 full-year result was -$185.0 million, down 478.12% from the prior year.
Restructuring Costs for Q1 2026 stood at -$45.0 million, down from -$3.0 million in the prior quarter.
The five-year high for Restructuring Costs was -$3.0 million in Q3 2024, with the low at -$45.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Genmab A	48.34 Bn	46.82 Bn	831.00 Mn

Download Data